Kalvista pharmaceuticals enters into non-dilutive synthetic royalty financing with dri healthcare trust

Cambridge, mass. & salisbury, england--(business wire)--kalvista pharmaceuticals, inc. (nasdaq: kalv) (“kalvista”), today announced the closing of a synthetic royalty financing agreement with dri healthcare trust (“dri”) for up to $179 million, comprised of a $100 million upfront payment, a one-time $22 million optional payment upon u.s. product approval, and up to $57 million in a sales-based milestone payment. the proceeds of this transaction will be used to fund the commercialization of sebe.
DRI Ratings Summary
DRI Quant Ranking